People taking Ozempic or other GLP1-RA diabetes/weight loss drugs are at higher risk of disruptions to their sense of taste or smell compared to people on other diabetes medications, according to international research. The team recruited 438,474 people diagnosed with type 2 diabetes and prescribed a GLP-RA, and matched them with 438,474 people of a similar demographic who were prescribed a different diabetes drug, monitoring them for issues with their taste and smell for up to two years. Overal